QR678 Neo, an Indian-developed patented biomimetic peptide formulation, achieved clinical validation in an international study. The Journal of Cosmetic and Laser Therapy published the breakthrough, marking a milestone in hair restoration science. Researchers in India, the USA, and Malaysia evaluated 112 men with advanced hair loss. They confirmed that QR678 Neo delivers 43 per cent better graft survival, fuller regrowth, and superior hair quality than conventional transplant methods.
Addressing poor graft survival
The innovation represents a leap forward in addressing one of hair transplantation’s longest-standing challenges — poor graft survival. Even with advanced Follicular Unit Extraction (FUE) techniques, inconsistent results and patchy regrowth often force patients to undergo repeat procedures. QR678 Neo changes this by supporting hair follicles before, during, and after surgery, ensuring stronger outcomes and faster recovery.
Beyond traditional storage mediums
Traditional storage mediums like cold saline or platelet-rich plasma (PRP) offer only temporary preservation. In contrast, QR678 Neo® actively supports biological activity throughout the transplant process. QR678 Neo® mimics natural growth factors with proprietary peptides to nourish the scalp, protect follicles, and boost transplanted hair regrowth. This regenerative approach improves follicle survival, accelerates healing, and enhances both density and quality of hair.
The therapy is administered in three stages — pre-surgery to rejuvenate the donor area, intra-surgery to protect extracted grafts, and post-surgery to strengthen regrowth. Global trial patients experienced denser hair growth, improved texture, faster healing, and fewer secondary procedures with QR678 Neo®.
Androgenetic alopecia affects most men by 50 and half of women by 60, driving rising demand for reliable transplant results. QR678 Neo® directly responds to this demand by raising the baseline for success rates in hair restoration.
Strengthening India’s global leadership
QR678 Neo®, patented in India and the United States and validated by 14+ global trials, demonstrates strong scalability and reproducibility. In clinical practice, QR678 Neo® consistently outperforms saline in follicle survival, regrowth rate, hair density, and patient satisfaction. It remains minimally invasive and well-tolerated.
The global hair restoration market now exceeds $4 billion. QR678 Neo® positions itself as a pioneering Indian-led innovation advancing regenerative therapy. It improves patient outcomes and strengthens India’s leadership in biotech-driven healthcare solutions.